Latest Secondary Market News

Page 5 of 5
BlackRock Investment Management (Australia) Limited has announced the upcoming distribution schedule for multiple Australian iShares ETFs, including important deadlines for investors opting into the Distribution Reinvestment Plan.
Claire Turing
Claire Turing
20 June 2025
Assetora Limited has been appointed as the new Responsible Entity of the DomaCom Fund, replacing Melbourne Securities Corporation Limited. This change is set to reopen the secondary market and resume new investments, signaling renewed investor confidence.
Claire Turing
Claire Turing
18 June 2025
CD Private Equity Fund II reported a steep decline in net profit for FY25, with earnings per unit plunging 98%, yet continued to deliver solid distributions to unitholders amid a challenging US private equity market.
Claire Turing
Claire Turing
30 May 2025
Metrics Master Income Trust (MXT) has successfully completed a $315 million wholesale placement, boosting its portfolio diversification and increasing its net asset value to approximately $2.44 billion.
Claire Turing
Claire Turing
30 May 2025
ReNu Energy has completed the sale of its hydrogen division and is set to acquire Janus Electric, a pioneer in electric truck battery swapping, backed by a substantial capital raise to scale operations.
Maxwell Dee
Maxwell Dee
30 Apr 2025
The Australian Office of Financial Management has issued a new 4.25% Treasury Bond due in 2036, set to begin trading on the ASX from February 13, 2025. This issuance adds a fresh long-term government debt instrument to the market.
Claire Turing
Claire Turing
7 Feb 2025
BlackRock Investment Management (Australia) Limited has announced estimated cash distributions for three Australian iShares ETFs, outlining key dates and reinvestment options for investors.
Claire Turing
Claire Turing
5 Feb 2025
Betashares Mrtn Currie Real Income Fund (RINC) units were suspended from trading on the ASX on 4 February 2025, following a prior announcement in December 2024. This suspension marks a significant operational shift for the managed fund.
Claire Turing
Claire Turing
4 Feb 2025
Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.
Victor Sage
Victor Sage
30 Jan 2025
DomaCom Limited reported a steep $4.5 million loss for the half-year ending December 2023, driven by declining revenues and operational hurdles, including a temporary suspension of its fund's Product Disclosure Statement. The company is actively pursuing capital raises to stabilize its position.
Claire Turing
Claire Turing
28 Jan 2025